This paper presents pharmacodynamic data for pancuronium in neonates, infants, children and adolescents during N20-0rfentanyl anaesthesia. Neuromuscular block (NMB) was evaluated by the adductor pollicis electromyogram. Dose-response curves of pancuronium were parallel in all age-groups. ED95 was greatest in children and least in infants (93 vs. 66 j1glkg, P < 0.05). The rate of spontaneous recovery following 95% NMB was comparable in all age-groups, as was the maintenance requirement of pancuronium when related to ED-values. The hourly requirement to maintain NMB > 85% was 60-68% of the individual ED95 dose.
Patient characteristics are shown in Table 1 . Neonates were 38-41 weeks of gestational age and their birth weights ranged from 3.1 to 3.8 kg. Neonates and infants did not receive any premedication. Children and adolescents received oral flunitrazepam 0.06 mglkg (maximum dose 2.0 mg). After glycopyrrolate 5 ).lglkg, induction of general anaesthesia was effected with fentanyl 3 ).lglkg and thiopentone 2-5 mg/kg. Ventilation (nitrous oxide in oxygen 2:1) was controlled to maintain end-tidal carbon dioxide at 5.0-5.5%. During the maintenance of anaesthesia, fentanyl 1-2 ).lglkg and halothane 0.2-0.5% (inspired) were given when indicated. Body temperature was maintained at > 36°C and the hands covered with light dressing to prevent surface cooling. Five per cent dextrose in 60 mMolll of saline· was given at a rate of 6 ml/kg/h intravenously. Blood loss did not exceed 2% of calculated blood volume.
When the patient was anaesthetized, the forearm and the fingers were supported and immobilised by a dorsal splint. 2 Hz train-of-four supramaximal stimuli were applied to the ulnar nerve at 20 sec intervals and the evoked compound adductor pollicis electromyogram (EMG) was recorded as an electrical difference between the surface electrodes attached on the thenar eminence over the adductor pollicis muscle and on the base of the middle finger (Relaxograph® , Datex, Helsinki, Finland). Once the EMG signal stabilised (less than 1 % change per minute in first twitch height and train-of-four ratio), cumulative pancuronium dose response curves were constructed. Precalculated doses were given at regular intervals on a logarithmic scale, with 14, 25, 45 and 82 ~glkg cumulative doses. Three unchanged first twitch and train-of-four responses were required before the next dose was given, to confirm the maximal response after every dose.
The maximal recorded neuromuscular block (NMB, percentage depression of first twitch response) after each cumulative pancuronium dose was plotted on log-probit paper. When NMB became > 70%, the final pancuronium incre.ment was individually calculated from the dose-response curve to produce a 95% NMB.13 At this stage, endotracheal intubation was performed and the twitch height allowed to recover spontaneously to 25% of the calibration value. Thereafter, and subsequently whenever the first twitch height recovered to 15% of the calibration value, a pancuronium increment of 114-115 of the individual ED95 dose (dose causing a 95% neuromuscular block) was given. At the end of surgery, residual NMB was reversed with neostigmine.
The following calculations were made: (1) Log-probit transformation and least square linear regression analysis were used to determine the individual ED IO , ED50 and ED95 of pancuronium and the slope of the dose-response 
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Reversal FIGURE 1.-A diagram to show the study design. First, a cumulative dose-response curve was created and individual ED-values calculated. Second, twitch height was allowed to recover to 2 S% of the calibration value and the recovery rate analysed. Third, small incremental doses were given to maintain twitch height at < IS% and durations of NMB maintained by a cumulative 50 J.l.g/kg dose and a cumulative ED50 dose were analysed. Fourth, pancuronium requirement for the hour following initial 25% twitch height recovery was related to individual ED95 dose. curve. The dose-response data were converted to a log-probit plot because this produces a linear doseresponse curve in the range of responses from < 5 to > 95%.14 (2) Spontaneous recovery rate of the twitch height was calculated as the time elapsed between 5 and 25% twitch heights. The'maximal twitch depression was used in these calculations if95% NMB was not reached during the construction of the doseresponse curve.
(3) The durations of NMB > 85% maintained by an additional cumulative 50 ~glkg dose and by a cumulative individual ED50 dose were measured. These doses and durations were calculated starting from the first pancuronium increment given after the initial recovery to 25% twitch height (see Figure 1 ). (4) Pancuronium requirement during the 60 minutes following endotracheal intubation was also calculated and related to an individual ED95 dose.
For statistical purposes, analysis of variance with Welch modification in cases of unequal variances and Bonferroni correction were used to make between-group comparisons. A P-value of < 0.05 was considered significant. Data are expressed as mean (SEM).
RESULTS
The dose-response curves were created before administration of halothane. Three to five pancuronium doses were given before the establishment ofthe average 95.2 (0.3)% NMB. The range of groups' mean maximal NMB was 95.8-94.6%. The mean maximum responses following incremental doses of pancuronium during the establishment of the dose-response curves were reached in 2.5, 3.5, 3.7 and 4.2 min in neonates, infants, children and adolescents, respectively (P < 0.05 between neonates and adolescents).
The slopes of the dose-response curves were identical in different patient groups, 6.6 (0.2) probits/log (the range of groups' mean slope being 6.5-6.8 probits/log). All but one neonate had an ED95 dose of pan cur onium at between 60-82 ~glkg. One neonate of 15 days of age had an ED95 dose of The rate of spontaneous recovery of the NMB (5-25% twitch height recovery) was comparable in each of the groups studied ( Table 2 ). After the twitch height recovery to 25%, the average inspired halothane concentration was 0.3% (similar between the groups).
The duration ofNMB > 85% maintained by the cumulative 50 Ilglkg dose of pancuronium given after the initial 25% twitch height recovery was During the first hour of anaesthesia the pancuronium requirement to maintain NMB > 85% was 60-68% of individual ED95 dose in different groups (no significant between-group differences).
DISCUSSION
The results of this study indicate that the ED-values of pancuronium are greater in children than in neonates, infants or adolescents. However, the rate of recovery of the pancuronium-induced neuromuscular block and the maintenance dose requirement, when related to individual ED-values, were similar in all age groups of paediatric patients. These pharmacodynamic properties are unique for pancuronium; with vecuronium, a pancuronium analogue, the ED-values, the rate of recovery and the maintenance requirement are clearly dependent on the age of the paediatric patient. 9 . 12 Laycock et a/. 8 found recently that the ED90 of pancuronium was 40-50% greater in children than in infants, a result strongly supported by the present study. Furthermore, we found that the average dose-response curves of neonates are close to the curves of infants. This means that children require more and neonates and infants less pancuronium than adolescents to achieve the same level of neuromuscular blockade. The changes in the ED-values during the patients' growth are most probably caused by sensitivity of neonates and infants to muscle relaxants, by differences in distribution volumes (a neonate contains 44% and a l-year-old child 26% extracellular fluid) and by different proportions of muscle mass in the body (muscle compartment increases from 25% to 42% of body weight during the growth from one to 15 years). 15 We cannot explain why one neonate was extremely resistant to pancuronium but Matteo et al. 16 found similar cases when they studied d-tubocurarine.
The present study shows a similar type of age dependency of the dose-response curves as that found with vecuronium. 10 However, the age related differences seem to be less with pancuronium: ED-values of pancuronium were 40% greater in children than in infants, whereas the difference was 73% with vecuronium and the potency ratio between vecuronium and pancuronium is 1.1-1.6 in different age groups of paediatric patients. If the effective doses are calculated on the basis of body surface area, the differences between age groups or the potency ratios are not any less. Therefore, the easiest way to calculate doses of muscle relaxants in clinical anaesthesia is based on the body weight.
The rate of twitch height recovery following equipotent doses of pancuronium did not depend on the patient's age. The time from 5 to 25% twitch height was 18 minutes, a figure comparable with the results of earlier studies. 2 ,4,5 However, it is not possible to determine the maintenance doserequirement from these recovery times. Therefore, we continued our study and analysed the subsequent doses of pancuronium required to maintain the twitch height at 5-15% during the course of anaesthesia. The duration of neuromuscular block maintained by the individual ED50 dose was similar in all age-groups. Furthermore, the hourly pancuronium requirement was 60-68% of the individual ED95 dose in all study groups. This maintenance requirement is comparable with that found in adults. 17 Our finding that a 50 Ilglkg dose of pancuronium maintained NMB for the shortest time in children mirrors the different potency of a constant dose in these age groups and does not contradict a uniform duration of effect following an equipotent dose. The fraction of ED95 dose required to maintain the NMB correlates with the elimination half-life of a neuromuscular blocking agent. IS Our results indicate that pancuronium, unlike vecuronium,19 is an equally long-acting neuromuscular blocking agent in adults and all age-groups of paediatric patients, when given in such equipotent doses.
The following example shows how an anaesthetist can utilise the above maintenance data in clinical practice. The twitch height of a patient recovers to 15% (three detectable responses with a train-of-four stimulus) in 30 minutes following pancuronium 100 Ilglkg. By this time the patient has 'needed' an ED95 dose and half of his hourly maintenance requirement (hourly requirement is 64% of ED95 dose). Thus, 100 Ilglkg equals 1.32 times individual ED95 dose. It is simple to calculate from these figures that the individual ED95 dose is 76 Ilg/kg and the maintenance requirement is 48 Ilg/kglh. Thus, subsequent increments of 20 Ilglkg are required every 25 min to maintain a > 85%
NMB.
This study showed that the dose of pan cur onium to establish a 95% neuromuscular block is smallest in neonates and infants and greatest in children. Neonates showed greater individual variability than other patients. Therefore, it would be prudent to use 25-30% less pancuronium for neonates and infants than for children. However, the rate of spontaneous recovery of twitch height was comparable in all age groups of paediatric patients. It confirms that the hourly maintenance dose was 60-68% of individual ED 95 . The results show that pancuronium is an equally long-acting neuromuscular blocking agent of all ages when equipotent doses are used.
